News
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...
Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...
3d
Investor's Business Daily on MSNThe Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.
Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...
A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...
Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.
Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results